403 related articles for article (PubMed ID: 29632215)
1. Soluble Klotho causes hypomineralization in Klotho-deficient mice.
Minamizaki T; Konishi Y; Sakurai K; Yoshioka H; Aubin JE; Kozai K; Yoshiko Y
J Endocrinol; 2018 Jun; 237(3):285-300. PubMed ID: 29632215
[TBL] [Abstract][Full Text] [Related]
2. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
3. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.
Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD
FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898
[TBL] [Abstract][Full Text] [Related]
4. Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype.
Bai X; Dinghong Q; Miao D; Goltzman D; Karaplis AC
Am J Physiol Endocrinol Metab; 2009 Jan; 296(1):E79-88. PubMed ID: 18984852
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization.
Shalhoub V; Ward SC; Sun B; Stevens J; Renshaw L; Hawkins N; Richards WG
Calcif Tissue Int; 2011 Aug; 89(2):140-50. PubMed ID: 21633782
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
7. Mineralized tissues in hypophosphatemic rickets.
Robinson ME; AlQuorain H; Murshed M; Rauch F
Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510
[TBL] [Abstract][Full Text] [Related]
8. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism.
Feng JQ; Ward LM; Liu S; Lu Y; Xie Y; Yuan B; Yu X; Rauch F; Davis SI; Zhang S; Rios H; Drezner MK; Quarles LD; Bonewald LF; White KE
Nat Genet; 2006 Nov; 38(11):1310-5. PubMed ID: 17033621
[TBL] [Abstract][Full Text] [Related]
9. Deletion of PTH rescues skeletal abnormalities and high osteopontin levels in Klotho-/- mice.
Yuan Q; Sato T; Densmore M; Saito H; Schüler C; Erben RG; Lanske B
PLoS Genet; 2012; 8(5):e1002726. PubMed ID: 22615584
[TBL] [Abstract][Full Text] [Related]
10. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic role of Fgf23 in Hyp mice.
Liu S; Zhou J; Tang W; Jiang X; Rowe DW; Quarles LD
Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E38-49. PubMed ID: 16449303
[TBL] [Abstract][Full Text] [Related]
12. FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model.
Xiao Z; King G; Mancarella S; Munkhsaikhan U; Cao L; Cai C; Quarles LD
JCI Insight; 2019 Dec; 4(23):. PubMed ID: 31801907
[TBL] [Abstract][Full Text] [Related]
13. Klotho expression in long bones regulates FGF23 production during renal failure.
Kaludjerovic J; Komaba H; Sato T; Erben RG; Baron R; Olauson H; Larsson TE; Lanske B
FASEB J; 2017 May; 31(5):2050-2064. PubMed ID: 28183805
[TBL] [Abstract][Full Text] [Related]
14. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO.
Xiao L; Naganawa T; Lorenzo J; Carpenter TO; Coffin JD; Hurley MM
J Biol Chem; 2010 Jan; 285(4):2834-46. PubMed ID: 19933269
[TBL] [Abstract][Full Text] [Related]
15. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
Fukumoto S
Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
[TBL] [Abstract][Full Text] [Related]
16. FGF23 suppresses chondrocyte proliferation in the presence of soluble α-Klotho both in vitro and in vivo.
Kawai M; Kinoshita S; Kimoto A; Hasegawa Y; Miyagawa K; Yamazaki M; Ohata Y; Ozono K; Michigami T
J Biol Chem; 2013 Jan; 288(4):2414-27. PubMed ID: 23235154
[TBL] [Abstract][Full Text] [Related]
17. FGF23 Is Not Required to Regulate Fetal Phosphorus Metabolism but Exerts Effects Within 12 Hours After Birth.
Ma Y; Kirby BJ; Fairbridge NA; Karaplis AC; Lanske B; Kovacs CS
Endocrinology; 2017 Feb; 158(2):252-263. PubMed ID: 27929669
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization.
Liu S; Gupta A; Quarles LD
Curr Opin Nephrol Hypertens; 2007 Jul; 16(4):329-35. PubMed ID: 17565275
[TBL] [Abstract][Full Text] [Related]
20. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
Ichikawa S; Austin AM; Gray AK; Econs MJ
J Bone Miner Res; 2012 Feb; 27(2):453-60. PubMed ID: 22006791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
